Virtudes Soriano

Virtudes Soriano

UNVERIFIED PROFILE

Are you Virtudes Soriano?   Register this Author

Register author
Virtudes Soriano

Virtudes Soriano

Publications by authors named "Virtudes Soriano"

Are you Virtudes Soriano?   Register this Author

21Publications

985Reads

13Profile Views

TERT promoter mutation subtypes and survival in stage I and II melanoma patients.

Int J Cancer 2019 03 4;144(5):1027-1036. Epub 2018 Oct 4.

Department of Dermatology, Instituto Valenciano de Oncología, València, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.31780DOI Listing
March 2019

Value of sentinel lymph node biopsy and adjuvant interferon treatment in thick (>4 mm) cutaneous melanoma: an observational study.

Eur J Dermatol 2016 Jan-Feb;26(1):34-48

School of Medicine, Universidad Católica de Valencia, Valencia, Spain, Department of Dermatology, Instituto Valenciano de Oncología, c/ Profesor Beltrán Báguena, 8 46009 Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2015.2693DOI Listing
December 2016

TERT promoter mutations in melanoma survival.

Int J Cancer 2016 Jul 2;139(1):75-84. Epub 2016 Mar 2.

Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.30042DOI Listing
July 2016

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.

Melanoma Res 2016 06;26(3):278-83

aMedical Oncology Service, Hospital Universitario La Paz bMedical Oncology Service, Hospital Ramón y Cajal cMedical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañon dMedical Oncology Service, Hospital La Princesa eMedical Affairs, Merck Sharp & Dohme, Madrid fMedical Oncology Service, Instituto Valenciano de Oncología gMedical Oncology Service, Hospital General Universitario de Valencia hMedical Oncology Service, Hospital La Fe, Valencia iMedical Oncology Service, Hospital Clinic de Barcelona, Barcelona jMedical Oncology Service, Hospital de Basurto, Bilbao kMedical Oncology Service, Hospital Teresa Herrera, La Coruña lMedical Oncology Service, Hospital Central de Asturias, Oviedo mMedical Oncology Service, Hospital General Universitario Santa Lucía, Cartagena nMedical Oncology Service, Hospital de Cruces, San Vicente de Baracaldo oMedical Oncology Service, Hospital Universitario Virgen de la Victoria, Málaga pDermatology Service, Complejo Asistencial Universitario de León, León qMedical Oncology Service, Hospital Miguel Servet, Zaragoza rMedical Oncology Service, Hospital Virgen de la Macarena, Sevilla sMedical Oncology Service, Hospital Clínico Universitario de Valladolid, Valladolid tMedical Oncology Service, Hospital Clínico Universitario de Santiago, Santiago de Compostela uMedical Oncology Service, Clínica Universitaria de Navarra, Pamplona, Spain vGlobal Health Outcomes Research, Merck Sharp & Dohme, Kenilworth, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861701PMC
June 2016

Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

Melanoma Res 2014 Dec;24(6):577-83

aMedical Oncology, Hospital General Valencia bMedical Oncology, Instituto Valenciano de Oncologia, Valencia cMedical Oncology, Hospital Clinic i Provincial dMedical Oncology, Hospital Vall d´Hebron, Barcelona eMedical Oncology, Hospital 12 de Octubre fMedical Oncology, Hospital La Paz gMedical Oncology, Hospital MD Anderson Cancer Center, Madrid hMedical Oncology, Hospital ClinicoVirgen de la Victoria, Malaga iMedical Oncology, Hospital Virgen de las Nieves, Granada jMedical Oncology, Clinica Universitaria de Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457498PMC
December 2014

A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.

Authors:
Simon N Stacey Patrick Sulem Aslaug Jonasdottir Gisli Masson Julius Gudmundsson Daniel F Gudbjartsson Olafur T Magnusson Sigurjon A Gudjonsson Bardur Sigurgeirsson Kristin Thorisdottir Rafn Ragnarsson Kristrun R Benediktsdottir Bjørn A Nexø Anne Tjønneland Kim Overvad Peter Rudnai Eugene Gurzau Kvetoslava Koppova Kari Hemminki Cristina Corredera Victoria Fuentelsaz Pilar Grasa Sebastian Navarrete Fernando Fuertes Maria D García-Prats Enrique Sanambrosio Angeles Panadero Ana De Juan Almudena Garcia Fernando Rivera Dolores Planelles Virtudes Soriano Celia Requena Katja K Aben Michelle M van Rossum Ruben G H M Cremers Inge M van Oort Dick-Johan van Spronsen Jack A Schalken Wilbert H M Peters Brian T Helfand Jenny L Donovan Freddie C Hamdy Daniel Badescu Ovidiu Codreanu Mariana Jinga Irma E Csiki Vali Constantinescu Paula Badea Ioan N Mates Daniela E Dinu Adrian Constantin Dana Mates Sjofn Kristjansdottir Bjarni A Agnarsson Eirikur Jonsson Rosa B Barkardottir Gudmundur V Einarsson Fridbjorn Sigurdsson Pall H Moller Tryggvi Stefansson Trausti Valdimarsson Oskar T Johannsson Helgi Sigurdsson Thorvaldur Jonsson Jon G Jonasson Laufey Tryggvadottir Terri Rice Helen M Hansen Yuanyuan Xiao Daniel H Lachance Brian Patrick O Neill Matthew L Kosel Paul A Decker Gudmar Thorleifsson Hrefna Johannsdottir Hafdis T Helgadottir Asgeir Sigurdsson Valgerdur Steinthorsdottir Annika Lindblom Robert S Sandler Temitope O Keku Karina Banasik Torben Jørgensen Daniel R Witte Torben Hansen Oluf Pedersen Viorel Jinga David E Neal William J Catalona Margaret Wrensch John Wiencke Robert B Jenkins Eduardo Nagore Ulla Vogel Lambertus A Kiemeney Rajiv Kumar José I Mayordomo Jon H Olafsson Augustine Kong Unnur Thorsteinsdottir Thorunn Rafnar Kari Stefansson

Nat Genet 2011 Sep 25;43(11):1098-103. Epub 2011 Sep 25.

deCODE genetics, Reykjavik, Iceland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263694PMC
September 2011